Amoéba shares climbed over 21% on the Paris market on Monday, following the cancellation of the issue of a new tranche of bonds convertible into shares (OCA), a financing method considered to be particularly dilutive.

The company - which has developed a biological process capable of eliminating bacterial risk in water and human wounds - explains that it has terminated its contract for the issue of bonds convertible into shares with Nice & Green.

This decision means that Amoéba will not be issuing an optional eighth tranche of 80 OCAs, as initially provided for in the contract.

In order to adapt its financial strategy to its industrial transformation objectives, Amoéba says it has signed a support contract with Redbridge Debt and Treasury Advisory to assist it in its search for financing.

This support will take place in two phases: (1) firstly, the search for the optimum financing strategy, and (2) secondly, support in the financing operations until a package of 45 million euros is obtained.

For the record, Amoéba intends to build a production plant dedicated to biocontrol products, which could produce 40 tonnes of active substance per year, equivalent to 100.000 hectares treated.

In order to finance this production site - which should be operational by early 2025 - then start marketing its products in Europe and the United States and pursue its activities over the next three years, the company estimates its total financial requirements at 45 million euros.

Copyright (c) 2023 CercleFinance.com. All rights reserved.